Company / Capital Expenditures
Editas Medicine, Inc. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$8.8M
FY2025
5-year range
$4.1M / $8.8M
FY2021-FY2025
Trend
+114.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 8 years, ranging from $2M in FY2019 to $9M in FY2025.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +13.2%.
Improved from $8M to $9M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +7.2%
- 5-Year CAGR
- +13.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +13.2%, indicating consistent growth.
- In FY2025, capital expenditures increased 114.3% year-over-year.
- Lowest capital expenditures in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.8M | +114.3% |
| FY2024 | $4.1M | -48.4% |
| FY2023 | $8.0M | +11.4% |
| FY2022 | $7.2M | +16.1% |
| FY2021 | $6.2M | +29.7% |
| FY2020 | $4.8M | +130.9% |
| FY2019 | $2.1M | -41.1% |
| FY2018 | $3.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026